STOCK TITAN

Hydreight Reports 132% YoY Revenue Increase in Q3 2025 and Fourth Consecutive Quarter of Profitability, Highlighting Strong Multi-Vertical Performance

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags

Hydreight (OTCQB: HYDTF) reported Q3 2025 GAAP revenue of $10.52M, up 132% YoY, and record topline of $12.83M (+110% YoY). The company posted GAAP net income of $361,888 for Q3 vs a loss in Q3 2024 and adjusted EBITDA of $619,752, marking the fourth consecutive profitable quarter. Cash on hand was $18.64M at quarter-end.

Operational highlights include ~295,000 VSDHOne product orders processed in Q3, nurse sign-ups up ~49% Q3 YoY, pharmacy orders +~72% YoY, and a definitive agreement to acquire a 5% stake in Perfect Scripts with option to 40%. The company closed an $11.5M convertible debenture in 2025 and continues VSDHOne platform expansion and integration efforts.

Loading...
Loading translation...

Positive

  • GAAP revenue +132% YoY to $10.52M in Q3 2025
  • Topline revenue of $12.83M in Q3 2025 (+110% YoY)
  • Adjusted EBITDA of $619,752 in Q3 2025, indicating operational improvement
  • Cash on hand of $18.64M at quarter-end
  • ~295,000 VSDHOne product orders processed in Q3 2025

Negative

  • $11.5M convertible debenture offering closed in 2025, posing potential shareholder dilution
  • Q3 2025 GAAP net income was modest at $361,888 despite strong revenue growth
  • VSDHOne meaningfully began operating only late June 2025, indicating limited operating history for recent platform revenue

News Market Reaction

-9.79%
1 alert
-9.79% News Effect

On the day this news was published, HYDTF declined 9.79%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Q3 2025 GAAP revenue: $10.52 million Q3 2025 topline revenue: $12.83 million Q3 2025 Adjusted EBITDA: $619,752 +5 more
8 metrics
Q3 2025 GAAP revenue $10.52 million Q3 2025, up 132% YoY vs Q3 2024
Q3 2025 topline revenue $12.83 million Record topline, up 110% YoY vs Q3 2024
Q3 2025 Adjusted EBITDA $619,752 Fourth consecutive profitable quarter
Q3 2025 GAAP Net Income $361,888 Compared to GAAP net loss of $89,938 in Q3 2024
Cash on hand $18.64 million Quarter-end cash balance as of September 30, 2025
VSDHOne Q3 product orders 295,000 orders Orders processed between July and September 2025
Nurse sign-ups Q3 2025 198 vs 133 49% YoY increase in nurse network sign-ups July–September
Convertible debenture offering $11.5 million Oversubscribed offering closed September 4, 2025

Market Reality Check

Price: $2.85 Vol: Price up 3.15% with volum...
low vol
$2.85 Last Close
Volume Price up 3.15% with volume 17,157 vs 20-day average 67,783, indicating light trading interest into the print. low
Technical Shares at $3.2996, trading above 200-day MA of $2 and 17.3% below the 52-week high.

Peers on Argus

Peers in Health Information Services were mostly flat to slightly negative, with...

Peers in Health Information Services were mostly flat to slightly negative, with names like AINMF down 0.83% and VHIBF down 0.15%, while others were unchanged, suggesting HYDTF’s move was stock-specific rather than sector-driven.

Historical Context

5 past events · Latest: Dec 02 (Positive)
Pattern 5 events
Date Event Sentiment Move Catalyst
Dec 02 Corporate update Positive +26.2% Reiterated Q3 growth, VSDHOne metrics, cash and 2026 focus areas.
Nov 26 Earnings release Positive -9.8% Reported Q3 revenue growth, profitability, strong cash and platform scaling.
Nov 20 Awards recognition Positive -0.8% Ranked #77 on Deloitte Technology Fast 500, highlighting rapid growth.
Oct 23 Corporate update Positive +13.3% Corporate update with cash position, VSDHOne orders and Fast 50 rank.
Sep 19 AGM results Neutral +0.0% AGM approvals including omnibus equity plan for up to 9M shares.
Pattern Detected

Positive operational and recognition news has often led to strong upside moves, but there are instances where similarly positive updates saw flat or negative next-day reactions.

Recent Company History

This announcement continues a string of positive updates for Hydreight in 2025. Prior releases highlighted Deloitte Fast 50/500 rankings, strong VSDHOne order growth (~295,000 orders in Q3), improved liquidity with an $11.5M convertible debenture, and multiple quarters of profitability. The Nov 2 corporate update reiterated Q3 metrics, cash of $18.64M, and 2026 priorities. Against that backdrop, today’s Q3 earnings release reinforces the same growth and profitability trajectory, adding more detailed financial disclosure and confirming a fourth consecutive profitable quarter.

Market Pulse Summary

The stock moved -9.8% in the session following this news. A negative reaction despite strong Q3 metr...
Analysis

The stock moved -9.8% in the session following this news. A negative reaction despite strong Q3 metrics would fit past instances where positive news, such as rankings or earnings, did not always translate into gains. The company delivered GAAP revenue of $10.52M and net income of $361,888, yet earlier positive items sometimes saw divergence between fundamentals and price. In such a scenario, attention may focus on expectations already embedded in the stock, prior capital raises, and execution risk around scaling VSDHOne and multi-vertical operations.

Key Terms

GAAP, Adjusted EBITDA, non-GAAP, telehealth, +3 more
7 terms
GAAP financial
"First 9 months GAAP revenue was $20.44 million an increase of 70%..."
GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.
Adjusted EBITDA financial
"Q3, 2025 Adjusted EBITDA¹ of $620K, marking continued operational improvement"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
non-GAAP financial
"The Company believes the following Non-GAAP1 financial measures provide meaningful insight..."
Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.
telehealth technical
"an enhanced version of the Company’s telehealth platform designed to deliver greater automation..."
Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.
convertible debenture financial
"Oversubscribed $11.5 Million Convertible Debenture Offering, Including Full Exercise..."
A convertible debenture is a long-term loan a company issues that pays interest like a bond but can be turned into a set number of the company’s shares under pre-agreed terms. For investors it matters because it mixes safety and upside: you get regular interest and higher repayment priority like a lender, yet you also hold an option to become a shareholder if the stock rises, which can dilute existing owners and change risk and return profiles.
GLP-1 medical
"growth across GLP-1 weight-management, hormone therapy, NAD, hair restoration..."
GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.
NAD+ medical
"Hydreight Technologies Expands Telehealth Offerings with Launch of NAD+ Therapy..."
NAD+ is a naturally occurring molecule that helps cells turn food into usable energy and repair damage, acting like a battery and maintenance signal inside every cell. It matters to investors because drugs, supplements, or diagnostics that raise or measure NAD+ levels are a growing area of medical and consumer interest, with potential revenue, regulatory scrutiny, and clinical risk tied to claims about aging, metabolism, and disease treatment.

AI-generated analysis. Not financial advice.

“The quarter reflects broad growth across all verticals, expanding VSDHOne adoption, and strategic investments aimed at supporting margin improvement and 2026 objectives. We exceeded our internal metrics across all verticals, reinforcing the strength of our strategy. A key focus has been onboarding and expanding our VSDHOne customers and services, supported by our investment in making the VSDHOne platform fully modular—allowing customers to adopt it module by module based on their needs. These initiatives position us to scale efficiently and achieve our 2026 objectives.” – Shane Madden, CEO of Hydreight

VANCOUVER, British Columbia and LAS VEGAS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) ( TSXV: NURS )( OTCQB: HYDTF )( FSE: SO6 ), a rapidly expanding mobile clinical network and medical platform which enables flexible at-home medical services across 50 states in the United States, is pleased to announce its financial results for the three and nine months ended September 30, 2025. All financial information is presented in Canadian dollars unless otherwise indicated.

Q3 2025 Highlights

  • First 9 months topline¹ revenue was $26.71 million an increase of 61% compared to the same period last year.
  • First 9 months GAAP revenue was $20.44 million an increase of 70% compared to the same period last year.
  • Q3, 2025 topline¹ record revenue of $12.83 million, an increase of 110% compared to Q3, 2024.
  • Q3, 2025 GAAP revenue was $10.52 million an increase of 132% compared to Q3, 2024.
  • Q3, 2025 Gross Margin of $2.33 million, up from $1.53 million in Q3 2024
  • Q3, 2025 Adjusted EBITDA¹ of $620K, marking continued operational improvement
  • Q3, 2025 GAAP Net Income of 362K, from GAAP Net Loss of $90K in Q3, 2024
  • Cash on Hand of $18.64 million at quarter-end
  • The Company received independent analyst coverage in 2025 from Maxim Group, Beacon Securities, and Canaccord Genuity, and continues to explore opportunities to broaden its independent research coverage.
  • Hydreight Technologies Signs Definitive Agreement to Acquire 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase to 40%, and Establish Strategic Partnership
  • ~295,000 VSDHOne product orders processed between July and September, reflecting broad growth across GLP-1 weight-management, hormone therapy, NAD, hair restoration, genetic testing, Ondanestron and more.
  • Nurse network expansion: 198 new nurse sign-ups between July and September vs. 133 during the same period last year (+49% YoY); 593 sign-ups in the first nine months of 2025 vs. 364 in 2024 (~63% YoY).
  • Pharmacy orders increased approximately 72% year-over-year, reflecting sustained growth and broader adoption across multiple wellness verticals.
  • M&A pipeline: Active evaluation of profitable multi-state wellness and digital-health operators that can scale nationally through VSDHOne.
  • Infrastructure and Technology Growth: Further integration of 503A/503B pharmacy partners to increase capacity, fulfillment speed, and margin potential, alongside the upcoming release of VSDHOne V2 — an enhanced version of the Company’s telehealth platform designed to deliver greater automation, scalability, and modular functionality for partners nationwide.
  • Hydreight was recognized again in 2025 as one of Canada’s Technology Fast 50™ award winners as well as one of Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™

Shane Madden, CEO of Hydreight, commented: “We are very pleased with the momentum behind VSDHOne. Although we announced the business at the end of last year, the platform only began operating in a meaningful way toward the end of June, and since then it has contributed to both revenue growth and sustained profitability. This progress reflects the development of our modular infrastructure and the legal framework that supports long-term scale. The next version of VSDHOne will build on this foundation with added automation, new services, and expanded partner integrations. As we move forward, our focus remains on operational discipline and careful financial planning to support continued growth and prepare for 2026.

️Upcoming Earnings Call

Hydreight Technologies will host a live earnings call to discuss its Q3, 2025 results, provide a business update, and share insights into the Company’s strategic priorities for 2025.

Date & Time: Friday November 28th, 2025 at 11:00am - 12:00pm PST
Registration Link: https://hydreight.zoom.us/webinar/register/WN_ddVQpLHgSgijH1rSbDO35g

The event will include a formal presentation followed by a Q&A session with investors.

The Company believes the following Non-GAAP1 financial measures provide meaningful insight to aid in the understanding of the Company’s performance and may assist in the evaluation of the Company’s business relative to that of its peers:

       
 Three months ended September 30,Nine months ended September 30,
  2025 2024 % change 2025 2024 % change
       
Adjusted Revenue$12,833,898$6,122,257 110%$26,710,651$16,578,742 61%
Deduct - deferred business partner contract revenue 86,889 50,160   739,823 (253,753) 
Deduct - business partner payouts on app service gross revenue 2,227,471 1,545,776   5,534,649 4,828,357  
GAAP Revenue$10,519,538$4,526,320 132%$20,436,179$12,004,138 70%
       
Adjusted Gross Margin$2,417,209$1,583,331 53%$6,504,810$4,070,549 60%
Deduct - deferred business partner contract revenue 86,889 50,160   739,823 (253,753) 
GAAP Gross Margin$2,330,320$1,533,171 52%$5,764,987$4,324,302 33%
       
Adjusted EBITDA$619,752$47,690 1200%$965,135$219,525 340%
Deduct - amortization and depreciation 116,657 47,094   324,790 118,283  
Deduct - share-based payments 7,062 90,534   73,542 526,988  
Deduct - interest and accretion 134,145 -   134,145 -  
GAAP Net Income (Loss)$361,888$(89,938)502%$432,658$(425,746)202%

Refer to Use of Non-GAAP Financial Measures

The table below sets out a summary of certain financial results of the Company over the past eight quarters and is derived from the audited annual consolidated financial statements and unaudited quarterly consolidated financial statements of the Company.

       
Fiscal Quarter EndedRevenue Net Income (Loss)
After Taxes
Comprehensive
Income (Loss)
Basic Income
(Loss) Per Share
Diluted Income
(Loss) Per Share
September 30, 202510,519,538 361,888 242,317 0.01 0.01 
June 30, 20255,376,519 49,867 160,779 0.00 0.00 
March 31, 20254,540,122 20,903 21,652 0.00 0.00 
December 31, 20244,040,578 20,577 (106,396)0.00 0.00 
September 30, 20244,526,320 (89,938)(53,119)(0.00)(0.00)
June 30, 20244,100,212 (27,087)(48,184)(0.00)(0.00)
March 31, 20243,377,606 (308,721)(370,559)(0.01)(0.01)
December 31, 20233,373,193 (898,561)(865,068)(0.02)(0.02)
       

Please see SEDAR+ for the Company's Q3 condensed consolidated interim financial statements and MD&A and for its audited annual consolidated financial statements for the year ended December 31, 2024.

The Company has experienced dramatic user growth over the past two years as can be seen by the consistent revenue growth over the past eight quarters. Net loss and comprehensive loss have improved from 2023 and into 2025, with the current quarter reflecting net income. 

Highlights and Subsequent Events

The $4.9 Trillion Opportunity in U.S. Healthcare

The U.S. healthcare market, valued at $4.9 trillion in 2023 (source: CMS.gov), represents one of the most complex and fragmented systems globally. Yet, as thought leaders like Marc Andreessen and a16z have pointed out, this fragmentation creates a trillion-dollar opportunity for innovation.

On behalf of the Board of Directors
Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.

Contact

Email: ir@hydreight.com; Telephone: (702) 970-8112

Hydreight Technologies Inc Ranked Number 56 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Hydreight Technologies Recognized as a Top 50 TSX Venture Exchange Company

This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

About Hydreight Technologies Inc.

Hydreight Technologies Inc is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform has hosted a network of over 3000 nurses, over 300 doctors and a pharmacy network through its Doctor networks across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.

About VSDHOne - Direct to Consumer Platform

Developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight Technologies launched the VSDHOne (Read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (“TRT”), hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, and modular end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

Use of Non-GAAP Financial Measures:

This release contains references to non-GAAP financial measures Adjusted Revenue, Adjusted Gross Margin and Adjusted EBITDA. The Company defines Adjusted Revenue as gross cash income before adjustment for the deferred portion of business partner contract revenue and gross receipts from Hydreight App service sales. The Company defines Adjusted Gross Margin as GAAP gross margin plus inventory impairment plus the deferred portion of business partner contract revenue. The Company defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization and before (i) transaction, restructuring, and integration costs and share-based payments expense, and (iii) gains/losses that are not reflective of ongoing operating performance. The Company believes that the measures provide information useful to its shareholders and investors in understanding the Company’s operating cash flow growth, user growth, and cash generating potential and may assist in the evaluation of the Company’s business relative to that of its peers more accurately than GAAP financial measures alone. This data is furnished to provide additional information and does not have any standardized meaning prescribed by GAAP. Accordingly, it should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP and is not necessarily indicative of other metrics presented in accordance with GAAP.

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

Cautionary Note Regarding Forward-Looking Information

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding expectations for the 2025 strategic outlook, Company's growth, Margins and VSDHOne’s and Hydreight’s growth and numbers in 2025.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company’s shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

¹See Use of Non-GAAP Financial Measures


FAQ

What were Hydreight (HYDTF) Q3 2025 GAAP revenue and year-over-year change?

Hydreight reported Q3 2025 GAAP revenue of $10.52M, a 132% increase YoY.

How profitable was Hydreight (HYDTF) in Q3 2025 and what was adjusted EBITDA?

Hydreight posted GAAP net income of $361,888 in Q3 2025 and adjusted EBITDA of $619,752.

How much cash did Hydreight (HYDTF) hold at the end of Q3 2025?

The company reported $18.64 million in cash on hand at quarter-end.

How many VSDHOne product orders did Hydreight process in Q3 2025?

Hydreight processed approximately 295,000 VSDHOne product orders between July and September 2025.

What recent financing could affect Hydreight (HYDTF) shareholders?

Hydreight closed an $11.5 million convertible debenture offering in 2025, which may have dilution implications for shareholders.

What acquisition or partnership did Hydreight (HYDTF) announce in 2025?

Hydreight signed a definitive agreement to acquire a 5% equity stake in Perfect Scripts, LLC with an option to increase to 40% and establish a strategic partnership.
Hydreight Tech

OTC:HYDTF

HYDTF Rankings

HYDTF Latest News

HYDTF Stock Data

134.37M
23.18M
57.76%
0.28%
Health Information Services
Healthcare
Link
United States
Las Vegas